The findings implied that 20(S)-protopanaxadiol might be a promising PURα agonist and the potential anti-tumor function of 20(S)-protopanaxadiol was supposed to be evaluated on cancers where PURα was discovered as a tumor suppressor in preclinical studies. Here, PURA is linked to cancer.